Web Desc
Functional Cures and the Eradication of HIV
joint with HIV Vaccines
Organizer(s): Lynn Morris, Melanie M. Ott and Kevin V. Morris
Date: March 24 - 28, 2019
Location: Fairmont Chateau Whistler, Whistler, BC, Canada
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Sponsored by Gilead Sciences, Inc.
For important information on the coronavirus, please click here
Summary of Meeting:
Human Immunodeficiency Virus type 1 (HIV) causes a persistent infection and results in acquired immunodeficiency syndrome (AIDS). AIDS has remained a global pandemic for over 40 years as HIV integrates into the genome of infected individuals and remains latent for years. Over the last decade, much emphasis has been centered on pathogenesis and vaccine development, but an emerging paradigm is taking place whereby targeted therapeutics are being developed to both control virus expression as well as possibly target viral infected cells for eradication. This conference for the first time brings together an interdisciplinary group of basic and applied scientists working on various aspects of HIV treatment and eradication strategies in an effort to translate our current understanding of HIV biology into meaningful therapeutics and/or eradication of HIV from infected individuals. To accomplish this goal, the conference aims to: 1) Introduce the state of the art in vaccine and neutralizing antibody strategies used to combat HIV; 2) Focus on transcriptional control and modulation of viral latency; and 3) Highlight synthetic biological approaches and genetic therapies currently being developed and clinically validated to combat HIV infection. The conference seeks to bring together an interdisciplinary mix of basic and applied scientists working on functional cures and eradication of HIV in an effort to better understand not only HIV treatment strategies but also the emerging technologies and approaches that will lead to the eventual eradication of HIV from infected individuals.
Global Health Travel Award Deadline: October 23 2018
Scholarship Deadline: December 5 2018
Discounted Abstract Deadline: December 5 2018
Abstract Deadline: December 18 2018
Discounted Registration Deadline: January 24 2019
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.


Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Bill & Melinda Gates FoundationGilead Sciences, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Gilead Sciences, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI143392-01
Funding for this conference was made possible (in part) by 1R13AI143392-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 24 | 4:00PM - 8:00PM
Arrival and Registration
Room: Macdonald Foyer


Sunday, March 24 | 6:00PM - 8:00PM
Welcome Mixer
Room: Macdonald Foyer
No registration fees are used to fund alcohol served at this function.

Monday, March 25 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac/Empress


Monday, March 25 | 8:00AM - 9:15AM
Welcome and Keynote Session (Joint)
Room: Macdonald ABCD

Speaker 1 of 4
* Ann J. Hessell, Oregon Health & Science University, USA

Monday, March 25 | 8:00AM - 9:15AM
Welcome and Keynote Session (Joint)
Room: Macdonald ABCD

Speaker 2 of 4
* Sharon R. Lewin, University of Melbourne, Australia

Monday, March 25 | 8:00AM - 9:15AM
Welcome and Keynote Session (Joint)
Room: Macdonald ABCD

Speaker 3 of 4
John R. Mascola, NIAID, National Institutes of Health, USA
Challenges and Opportunities for Antibody-Based HIV Vaccines

Monday, March 25 | 8:00AM - 9:15AM
Welcome and Keynote Session (Joint)
Room: Macdonald ABCD

Speaker 4 of 4
Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
Understanding Barriers to HIV Cure

Monday, March 25 | 9:15AM - 11:15AM
Antibodies for Prevention, Treatment and Cure (Joint)
Room: Macdonald ABCD

Speaker 1 of 7
* Sharon R. Lewin, University of Melbourne, Australia

Monday, March 25 | 9:15AM - 11:15AM
Antibodies for Prevention, Treatment and Cure (Joint)
Room: Macdonald ABCD

Speaker 2 of 7
* Ann J. Hessell, Oregon Health & Science University, USA

Monday, March 25 | 9:15AM - 11:15AM
Antibodies for Prevention, Treatment and Cure (Joint)
Room: Macdonald ABCD

Speaker 3 of 7
David D. Ho, Aaron Diamond AIDS Research Center, USA
Engineering Bispecific Antibodies to Prevent/Treat HIV Infection, Quantify Fc-Mediated Effector Functions, Measure Avidity Contribution to Virus Neutralization, and Infer HIV Envelope Spike Density

Monday, March 25 | 9:15AM - 11:15AM
Antibodies for Prevention, Treatment and Cure (Joint)
Room: Macdonald ABCD


Coffee Break

Monday, March 25 | 9:15AM - 11:15AM
Antibodies for Prevention, Treatment and Cure (Joint)
Room: Macdonald ABCD

Speaker 5 of 7
Florian Klein, University of Cologne, Germany
Broadly Neutralizing Antibodies for HIV-1 Immunotherapy

Monday, March 25 | 9:15AM - 11:15AM
Antibodies for Prevention, Treatment and Cure (Joint)
Room: Macdonald ABCD

Speaker 6 of 7
Ann Marie Carias, Northwestern University, USA
Short Talk: Distribution and Localization of I.V. injected VRC01 and VRC01-LS in the in vivo Rhesus Macaque Model

Monday, March 25 | 9:15AM - 11:15AM
Antibodies for Prevention, Treatment and Cure (Joint)
Room: Macdonald ABCD

Speaker 7 of 7
Sai Priya Anand, McGill University, Canada
Short Talk: Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells

Monday, March 25 | 11:15AM - 5:00PM
On Own for Lunch


Monday, March 25 | 11:15AM - 1:00PM
Poster Setup
Room: Frontenac/Empress


Monday, March 25 | 1:00PM - 10:00PM
Poster Viewing
Room: Frontenac/Empress


Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 1 of 10
* Leor S. Weinberger, University of California, San Francisco, USA

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 2 of 10
* Rasmi Thomas, U.S. Military HIV Research Program, USA

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 3 of 10
James Arthos, NIAID, National Institutes of Health, USA
A Role for MAdCAM and Retinoic Acid in Establishing Viral Replication in Gut-Associated Lymphoid Tissues

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 4 of 10
Evan Rossignol, Ragon Institute of MGH, MIT, and Harvard, USA
Development of Monoclonal Antibodies from Elite Controllers to Target the HIV Reservoir

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 5 of 10
Anjie Zhen, University of California, Los Angeles, USA
Checkpoint Inhibitor Dendritic Cell Vaccine Suppresses HIV-1 Replication

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 6 of 10
David F. G. Malone, University of Oxford, UK
CD56neg NK Cells Have Increased Functional Response to CD16 Stimulation in Chronic HIV

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 7 of 10
Riddhima Banga, Centre Hospitalier Universitaire Vaudois, Switzerland
PD-1/PD-L1 Interaction Modulates HIV-1 Transcription in Lymph Nodes of Treated Aviremic Individuals

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 8 of 10
Namita Satija, Icahn School of Medicine at Mount Sinai, USA
A Genetically Encoded Switch to Monitor HIV Infection and Latency within Humanized Mice Reveals HIV-Susceptibility Associated with Diverse T Cell Transcriptional States

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 9 of 10
Carly G K Ziegler, Massachusetts Institute of Technology, USA
Paired Host-Virus Single Cell Genomics Identifies Cell Types Harboring Virus in Humans and Non-Human Primates

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Immunology of HIV Cure
Room: Macdonald CD

Speaker 10 of 10
Alexander O. Pasternak, University of Amsterdam, Netherlands
CD32+CD4+ T Cells Are Highly Enriched in HIV DNA

Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Lessons from Non-Human Primate Studies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 1 of 9
* Willy Bogers, Biomedical Primate Research Centre, Netherlands


Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Lessons from Non-Human Primate Studies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 2 of 9
* Yuxing Li, University of Maryland, USA


Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Lessons from Non-Human Primate Studies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 3 of 9
Bridget Fisher, Seattle Children's Research Institute, USA
Oral Immunization with Native-Like HIV-1 Trimers Elicits Systemic Immune Responses and Cross-Clade Reactive Anti-V1V2 Antibodies


Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Lessons from Non-Human Primate Studies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 4 of 9
Miroslaw K. Gorny, New York University School of Medicine, USA
Tight Control of SHIV Challenge in Macaques with Vaccine-Induced Neutralizing and Non-Neutralizing Anti-V2 Antibodies


Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Lessons from Non-Human Primate Studies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 5 of 9
Paolo Lusso, NIAID, National Institutes of Health, USA
Induction of Cross-Clade Heterologous Tier-2 HIV-1 Neutralizing Antibodies by an mRNA-Based Vaccine in Macaques


Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Lessons from Non-Human Primate Studies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 6 of 9
Ma Luo, University of Manitoba, Canada
A Vaccine Targeting HIV Maturation Protects Cynomolgus Monkeys Against Vaginal SIVmac251 Acquisition


Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Lessons from Non-Human Primate Studies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 7 of 9
Mauricio A. Martins, University of Miami, USA
Anti-CTLA-4 Therapy Enhances Vaccine Immunogenicity but not Efficacy Against Simian Immunodeficiency Virus Challenge in Rhesus Macaques


Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Lessons from Non-Human Primate Studies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 8 of 9
Kimberly M. Cirelli, La Jolla Institute for Immunology, USA
Slow Delivery Immunization Enhances Germinal Center and Neutralizing Antibody Responses via Modulation of Immunodominance


Monday, March 25 | 2:30PM - 4:30PM
Workshop 1: Lessons from Non-Human Primate Studies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 9 of 9
Mario Roederer, NIAID, National Institutes of Health, USA
SIV Escapes from Non-neutralizing Antibodies Blocking a4ß7 Integrin Binding


Monday, March 25 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Monday, March 25 | 5:00PM - 7:00PM
Development of the Innate Cell and Antibody Responses to HIV
Room: Macdonald CD

Speaker 1 of 8
* Rebecca M. Lynch, George Washington University, USA

Monday, March 25 | 5:00PM - 7:00PM
Development of the Innate Cell and Antibody Responses to HIV
Room: Macdonald CD

Speaker 2 of 8
* Brian Moldt, Gilead Sciences, USA

Monday, March 25 | 5:00PM - 7:00PM
Development of the Innate Cell and Antibody Responses to HIV
Room: Macdonald CD

Speaker 3 of 8
Galit Alter, MIT and Harvard University, USA
Defining Conserved Correlates of Humoral Immune Protection Against SIV/SHIV

Monday, March 25 | 5:00PM - 7:00PM
Development of the Innate Cell and Antibody Responses to HIV
Room: Macdonald CD

Speaker 4 of 8
Michel C. Nussenzweig, HHMI/Rockefeller University, USA
Targeting B Lymphocytes to Control HIV-1

Monday, March 25 | 5:00PM - 7:00PM
Development of the Innate Cell and Antibody Responses to HIV
Room: Macdonald CD

Speaker 5 of 8
Mario Roederer, NIAID, National Institutes of Health, USA
Short Talk: SIV Escapes from Non-neutralizing Antibodies Blocking a4ß7 Integrin Binding

Monday, March 25 | 5:00PM - 7:00PM
Development of the Innate Cell and Antibody Responses to HIV
Room: Macdonald CD

Speaker 6 of 8
Jérémy Dufloo, Institut Pasteur, France
Short Talk: Complement Activation at the Surface of HIV-1-Infected Cells

Monday, March 25 | 5:00PM - 7:00PM
Development of the Innate Cell and Antibody Responses to HIV
Room: Macdonald CD

Speaker 7 of 8
Mariya B. Shapiro, Oregon Health & Science University, USA
Short Talk: Defining the Window of Opportunity for SHIV Clearance with bNAbs in Infant Macaques

Monday, March 25 | 5:00PM - 7:00PM
Development of the Innate Cell and Antibody Responses to HIV
Room: Macdonald CD

Speaker 8 of 8
Lynn Morris, National Institute for Communicable Diseases, South Africa
Genetic and Structural Features of HIV-1 V2-Specific Antibodies that Mediate ADCC and Block a4ß7 Interactions

Monday, March 25 | 5:00PM - 7:00PM
Clinical Trials for Prevention: Vaccines and Antibodies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 1 of 7
* Punnee Pitisuttithum, Mahidol University, Thailand


Monday, March 25 | 5:00PM - 7:00PM
Clinical Trials for Prevention: Vaccines and Antibodies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 2 of 7
* Susan W. Barnett, Bill & Melinda Gates Foundation, USA


Monday, March 25 | 5:00PM - 7:00PM
Clinical Trials for Prevention: Vaccines and Antibodies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 3 of 7
Fatima Laher, University of the Witwatersrand, South Africa
ALVAC-gp120 for Clade C in South Africa


Monday, March 25 | 5:00PM - 7:00PM
Clinical Trials for Prevention: Vaccines and Antibodies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 4 of 7
Shelly Krebs, Walter Reed Army Institute of Research, USA
Short Talk: B Cell Priming from RV144 Vaccination Impacts Post-Infection Antibody Responses


Monday, March 25 | 5:00PM - 7:00PM
Clinical Trials for Prevention: Vaccines and Antibodies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 5 of 7
Lawrence Corey, Fred Hutchinson Cancer Research Center, USA
Validating Neutralization as a Mechanistic Surrogate of Protection in Passive Antibody Studies


Monday, March 25 | 5:00PM - 7:00PM
Clinical Trials for Prevention: Vaccines and Antibodies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 6 of 7
Beatrice Ondondo, Cardiff Metropolitan University, UK
T-Cell Vaccine Trials for HIV


Monday, March 25 | 5:00PM - 7:00PM
Clinical Trials for Prevention: Vaccines and Antibodies
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 7 of 7
R. Keith Reeves, Harvard Medical School, USA
Short Talk: Human Memory NK Cells Are Potently Induced by HIV and HIV Vaccines


Monday, March 25 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac/Empress
No registration fees are used to fund alcohol served at this function.

Monday, March 25 | 7:30PM - 10:00PM
Poster Session 1
Room: Frontenac/Empress


Tuesday, March 26 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac/Empress


Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD

Speaker 1 of 10
* Ya-Chi Ho, Yale School of Medicine, USA

Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD

Speaker 2 of 10
* Joseph (Mike) McCune, Bill & Melinda Gates Foundation, USA

Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD

Speaker 3 of 10
Saba Valadkhan, Case Western Reserve University, USA
An HIV-Induced Mechanism for T Cell Quiescence and Proviral Latency

Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD

Speaker 4 of 10
Eric M. Verdin, Buck Institute for Research on Aging, USA
CRISPR-Based Characterizing of Latency-Associated Pathways

Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD


Coffee Break

Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD

Speaker 6 of 10
Jonathan Karn, Case Western Reserve University, USA
Signaling Pathways Controlling HIV Reactivation from Latency

Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD

Speaker 7 of 10
Ivan D'Orso, University of Texas Southwestern Medical Center, USA
Transcriptional Regulatory Mechanisms Shaping HIV Proviral Fate

Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD

Speaker 8 of 10
Joe D. Hiatt, University of California, San Francisco, USA
Short Talk: A Functional Map of HIV-Host Interactions in Primary Human CD4+ T cells

Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD

Speaker 9 of 10
Peter D. Sun, NIAID, National Institutes of Health, USA
Short Talk: Target HIV Viral Release Pathway as A New Antiviral Strategy

Tuesday, March 26 | 8:00AM - 11:15AM
Mechanisms of Viral Expression and Control of Host Cell Func
tion

Room: Macdonald CD

Speaker 10 of 10
Richard E. Sutton, Yale University School of Medicine, USA
Short Talk: Whole Exome Sequencing Identifies SNVs and Indels Associated with HIV+ Elite and Viremic Control

Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 1 of 10
* Ivelin Georgiev, Vanderbilt Vaccine Center, USA


Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 2 of 10
* Andrew B. Ward, The Scripps Research Institute, USA


Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 3 of 10
Gunilla B. Karlsson Hedestam, Karolinska Institutet, Sweden
Antibody Germline Genes and Impact on Vaccine Responses


Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 4 of 10
Steven E. Bosinger, Emory University, USA
In vivo Lineage Tracing of Antigen-Specific B Cells after Vaccination


Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 5 of 10
Ian Setliff, Vanderbilt Vaccine Center, USA
Short Talk: High-Throughput Mapping of B-Cell Receptor Sequence to Antigen Specificity


Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB


Coffee Break


Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 7 of 10
James E. Voss, The Scripps Research Institute, USA
Short Talk: Reprogramming the Antigen Specificity of B Cells Using Genome-Editing Technologies


Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 8 of 10
Adrian B. McDermott, National Institutes of Health, USA
Characterization of Antigen-Specific Memory B Cells Following Vaccination


Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 9 of 10
Colin Havenar-Daughton, Vir Biotechnology, USA
The Antigen-Specific Human Naive B Cell Repertoire: A Starting Point for Vaccine Responses


Tuesday, March 26 | 8:00AM - 11:15AM
New Technologies for Studying and Inducing B Cells
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 10 of 10
Kristin L. Boswell, NIAID, National Institutes of Health, USA
Short Talk: Bcl-6/Bcl-xL B Cell Immortalization for Antibody Discovery in Vaccination and Chronic Infection


Tuesday, March 26 | 11:15AM - 5:00PM
On Own for Lunch


Tuesday, March 26 | 11:15AM - 1:00PM
Poster Setup
Room: Frontenac/Empress


Tuesday, March 26 | 11:30AM - 1:00PM
Hands-On Computer Workshop on Los Alamos
HIV Sequences

Database
This session is from HIV Vaccines
Room: Macdonald EF
Bring your own laptop if you have one
Click here for more information


Tuesday, March 26 | 1:00PM - 10:00PM
Poster Viewing
Room: Frontenac/Empress


Tuesday, March 26 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Tuesday, March 26 | 5:00PM - 7:00PM
Mechanism and Modulation of Latency
Room: Macdonald CD

Speaker 1 of 7
* George B. Kyei, University of Ghana, Ghana

Tuesday, March 26 | 5:00PM - 7:00PM
Mechanism and Modulation of Latency
Room: Macdonald CD

Speaker 2 of 7
* Sharon R. Lewin, University of Melbourne, Australia

Tuesday, March 26 | 5:00PM - 7:00PM
Mechanism and Modulation of Latency
Room: Macdonald CD

Speaker 3 of 7
Melanie M. Ott, Gladstone Institutes, USA
Epigenetic Regulation of HIV Transcription

Tuesday, March 26 | 5:00PM - 7:00PM
Mechanism and Modulation of Latency
Room: Macdonald CD

Speaker 4 of 7
Monsef Benkirane, Institut de Genetique Humaine, France
HIV-Host Interactions at the Genomic Level

Tuesday, March 26 | 5:00PM - 7:00PM
Mechanism and Modulation of Latency
Room: Macdonald CD

Speaker 5 of 7
Leor S. Weinberger, University of California, San Francisco, USA
Discovery and Characterization of a Virus-Intrinsic HIV Latency Circuit

Tuesday, March 26 | 5:00PM - 7:00PM
Mechanism and Modulation of Latency
Room: Macdonald CD

Speaker 6 of 7
Luis M. Agosto, Boston Medical Center, USA
Short Talk: Identification of Novel Pathways that Regulate HIV Transcription using an Unbiased Functional Screen

Tuesday, March 26 | 5:00PM - 7:00PM
Mechanism and Modulation of Latency
Room: Macdonald CD

Speaker 7 of 7
Leah Plasek, Case Western Reserve University, USA
Short Talk: Investigation of Potential Roles for lncRNAs in Establishment and Maintenance of HIV Latency

Tuesday, March 26 | 5:00PM - 7:00PM
Antibody-Virus Coevolution: Vaccines and Lessons from Infect
ion
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 1 of 6
* Daniela Fera, Swarthmore College, USA


Tuesday, March 26 | 5:00PM - 7:00PM
Antibody-Virus Coevolution: Vaccines and Lessons from Infect
ion
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 2 of 6
Nicole A. Doria-Rose, NIAID, National Institutes of Health, USA
Broadly Neutralizing Antibodies: Lessons from Natural Infection


Tuesday, March 26 | 5:00PM - 7:00PM
Antibody-Virus Coevolution: Vaccines and Lessons from Infect
ion
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 3 of 6
Kevin O. Saunders, Duke University, USA
Short Talk: CH505 Transmitted/Founder Envelope Elicits Tier 2 Neutralizing Antibodies Against the CD4 Binding and V1V2-Glycan Sites during Human Infection and Macaque Vaccination


Tuesday, March 26 | 5:00PM - 7:00PM
Antibody-Virus Coevolution: Vaccines and Lessons from Infect
ion
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 4 of 6
Mattia Bonsignori, Duke University, USA
Inference of the VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier


Tuesday, March 26 | 5:00PM - 7:00PM
Antibody-Virus Coevolution: Vaccines and Lessons from Infect
ion
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 5 of 6
Elise Landais, International AIDS Vaccine Initiative, USA
Fast and Focused Maturation of a VRC01-Class Broadly Neutralizing Antibody Lineage


Tuesday, March 26 | 5:00PM - 7:00PM
Antibody-Virus Coevolution: Vaccines and Lessons from Infect
ion
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 6 of 6
Marit van Gils, Amsterdam UMC, Netherlands
Short Talk: Comparison of Monoclonal Antibodies Induced by BG505 SOSIP Trimer Immunization and BG505 SHIV Infection in Non-Human Primates


Tuesday, March 26 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac/Empress
No registration fees are used to fund alcohol served at this function.

Tuesday, March 26 | 7:30PM - 10:00PM
Poster Session 2
Room: Frontenac/Empress


Wednesday, March 27 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac/Empress


Wednesday, March 27 | 8:00AM - 11:00AM
Therapeutic Vaccines and Cure Strategies (Joint)
Room: Macdonald ABCD

Speaker 1 of 8
* Douglas F. Nixon, Weill Cornell Medicine, USA

Wednesday, March 27 | 8:00AM - 11:00AM
Therapeutic Vaccines and Cure Strategies (Joint)
Room: Macdonald ABCD

Speaker 2 of 8
* Tomas Hanke, University of Oxford, UK

Wednesday, March 27 | 8:00AM - 11:00AM
Therapeutic Vaccines and Cure Strategies (Joint)
Room: Macdonald ABCD

Speaker 3 of 8
Jintanat Ananworanich, US Military HIV Research Program, USA
AD26 & MVA Vaccines in Acutely Treated HIV: Safety, Immunogenicity and Viral Rebound

Wednesday, March 27 | 8:00AM - 11:00AM
Therapeutic Vaccines and Cure Strategies (Joint)
Room: Macdonald ABCD

Speaker 4 of 8
Beatriz Mothe, IrsiCaixa AIDS Research Institute-HIVACAT, Spain
Therapeutic Vaccines after Early ART: Impact on Reservoir

Wednesday, March 27 | 8:00AM - 11:00AM
Therapeutic Vaccines and Cure Strategies (Joint)
Room: Macdonald ABCD


Coffee Break

Wednesday, March 27 | 8:00AM - 11:00AM
Therapeutic Vaccines and Cure Strategies (Joint)
Room: Macdonald ABCD

Speaker 6 of 8
Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA
Attacking the Latent Reservoir with Convertible CAR-T Cells Programmed with HIV bNAbs

Wednesday, March 27 | 8:00AM - 11:00AM
Therapeutic Vaccines and Cure Strategies (Joint)
Room: Macdonald ABCD

Speaker 7 of 8
Eric Arts, Western University, Canada
Combining a TLR7 Agonist with a Heterologous Virus-Like Particle for Potent and Specific Latency Reversal in Patient Samples during Stable cART

Wednesday, March 27 | 8:00AM - 11:00AM
Therapeutic Vaccines and Cure Strategies (Joint)
Room: Macdonald ABCD

Speaker 8 of 8
Daniel Muli Muema, Africa Health Research Institute, South Africa
HIV Infection/FRESH

Wednesday, March 27 | 11:15AM - 5:00PM
On Own for Lunch


Wednesday, March 27 | 11:15AM - 1:00PM
Poster Setup
Room: Frontenac/Empress


Wednesday, March 27 | 11:30AM - 1:00PM
Hands-On Computer Workshop on Los Alamos
HIV Immunolog

y Database
This session is from HIV Vaccines
Room: Macdonald EF
Bring your own laptop if you have one
Click here for more information


Wednesday, March 27 | 1:00PM - 10:00PM
Poster Viewing
Room: Frontenac/Empress


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 1 of 10
* Alejandro Balazs, Massachusetts General Hospital, USA


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 2 of 10
* Linqi Zhang, Tsinghua University, China


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 3 of 10
Jacqueline Marlene Brady, Harvard Medical School, USA
Isotype-Dependent Protection Against Mucosal HIV Transmission in Humanized Mouse Models


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 4 of 10
Samantha Marie Townsley, Walter Reed Army Institute of Research, USA
Autoreactivity Mediated by Total IgG Is not Associated with the Development of Neutralization Breadth


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 5 of 10
Michael B. Zwick, The Scripps Research Institute, USA
An MPER Antibody that Neutralizes HIV Using Recognition Properties and Germline Genes Shared Among Donors


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 6 of 10
Rory Henderson, Duke University, USA
Antibody Fab Elbow Mutations Modulate Interdomain Flexibility and Dynamics of HIV-1 Broadly Neutralizing Antibodies


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 7 of 10
Ronnie M. Russell, University of Pennsylvania, USA
Antigenic Conservation of the V2 Apex Among Primate Lentiviruses


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 8 of 10
Marie Pancera, Fred Hutchinson Cancer Research Center, USA
Structural Basis for Potent Tier 2 Autologous Neutralization Elicited by Vaccination


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 9 of 10
Andres Finzi, CRCHUM, Université de Montréal, Canada
An Asymmetric Opening of HIV-1 Env Is Required for Anti-Cluster A Antibody Binding


Wednesday, March 27 | 2:30PM - 4:30PM
Workshop 2: Understanding Antibody and Envelope Structures
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 10 of 10
Kimmo Rantalainen, The Scripps Research Institute, USA
Electron Microscopic Characterization of HIV Envelope in Detergent Micelles, Lipid Bicelles and Nanodiscs


Wednesday, March 27 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Wednesday, March 27 | 5:00PM - 7:00PM
Experimental Molecular Approaches to Targeting Viral Reservo
irs

Room: Macdonald CD

Speaker 1 of 7
* Ramesh K. Akkina, Colorado State University, USA

Wednesday, March 27 | 5:00PM - 7:00PM
Experimental Molecular Approaches to Targeting Viral Reservo
irs

Room: Macdonald CD

Speaker 2 of 7
* Paula M. Cannon, University of Southern California, Keck School of Medicine, USA

Wednesday, March 27 | 5:00PM - 7:00PM
Experimental Molecular Approaches to Targeting Viral Reservo
irs

Room: Macdonald CD

Speaker 3 of 7
Romas Geleziunas, Gilead Sciences, Inc., USA
Attacking Latent Reservoirs

Wednesday, March 27 | 5:00PM - 7:00PM
Experimental Molecular Approaches to Targeting Viral Reservo
irs

Room: Macdonald CD

Speaker 4 of 7
Priti Kumar, Yale School of Medicine, USA
Direct in vivo Gene Engineering of Human T Cells for HIV Therapy

Wednesday, March 27 | 5:00PM - 7:00PM
Experimental Molecular Approaches to Targeting Viral Reservo
irs

Room: Macdonald CD

Speaker 5 of 7
Susana T. Valente, Scripps Florida, USA
Silencing the HIV Reservoir

Wednesday, March 27 | 5:00PM - 7:00PM
Experimental Molecular Approaches to Targeting Viral Reservo
irs

Room: Macdonald CD

Speaker 6 of 7
Chantelle L. Ahlenstiel, Kirby Institute, University of New South Wales, Australia
Short Talk: RNA-Directed Epigenetic Silencing Protects Humanized Mice during HIV Challenge

Wednesday, March 27 | 5:00PM - 7:00PM
Experimental Molecular Approaches to Targeting Viral Reservo
irs

Room: Macdonald CD

Speaker 7 of 7
Fabio Romerio, University of Maryland School of Medicine, USA
Short Talk: The HIV-1 Antisense Transcript Ast Induces Viral Latency via Several Silencing Pathways

Wednesday, March 27 | 5:00PM - 7:00PM
T Cells in HIV Vaccination and Acute Infection
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 1 of 7
* Barbara L. Shacklett, University of California, Davis, USA


Wednesday, March 27 | 5:00PM - 7:00PM
T Cells in HIV Vaccination and Acute Infection
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 2 of 7
* Diane L. Bolton, US Military HIV Research Program, WRAIR, USA


Wednesday, March 27 | 5:00PM - 7:00PM
T Cells in HIV Vaccination and Acute Infection
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 3 of 7
Christian Brander, Institut de Recerca de la Sida, IrsiCaixa, Spain
Vaccine-Elicited T Cells in Clinical Trials


Wednesday, March 27 | 5:00PM - 7:00PM
T Cells in HIV Vaccination and Acute Infection
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 4 of 7
Stephen A. Migueles, NIAID, National Institutes of Health, USA
Short Talk: Ad5/HIV Vaccines Induce CD8+ T Cells with Insufficient Avidity to Kill HIV-Infected CD4+ T Cells


Wednesday, March 27 | 5:00PM - 7:00PM
T Cells in HIV Vaccination and Acute Infection
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 5 of 7
David B. Masopust, University of Minnesota, USA
Tissue-Resident T Cells


Wednesday, March 27 | 5:00PM - 7:00PM
T Cells in HIV Vaccination and Acute Infection
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 6 of 7
Jonah B. Sacha, Oregon Health & Science University, USA
Unconventional T Cells: Potential for Induction by Vaccination


Wednesday, March 27 | 5:00PM - 7:00PM
T Cells in HIV Vaccination and Acute Infection
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 7 of 7
Leticia Kuri-Cervantes, University of Pennsylvania, USA
Short Talk: Longitudinal Dynamics of Follicular CD4+ T Cells in Acute SIV Infection


Wednesday, March 27 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac/Empress
No registration fees are used to fund alcohol served at this function.

Wednesday, March 27 | 7:30PM - 10:00PM
Poster Session 3
Room: Frontenac/Empress


Thursday, March 28 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac/Empress


Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD

Speaker 1 of 10
* Zabrina L. Brumme, Simon Fraser University, Canada

Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD

Speaker 2 of 10
* Eric M. Verdin, Buck Institute for Research on Aging, USA

Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD

Speaker 3 of 10
David M. Margolis, University of North Carolina at Chapel Hill, USA
Progress Towards Targeting and Eradication of HIV in Models and Man

Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD

Speaker 4 of 10
Sharon R. Lewin, University of Melbourne, Australia
Understanding Natural Variation in HIV Transcription on Antiretroviral Therapy: New Approaches to Reverse HIV Latency

Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD


Coffee Break

Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD

Speaker 6 of 10
Deborah Persaud, Johns Hopkins University School of Medicine, USA
Latency and HIV in Pediatric Populations

Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD

Speaker 7 of 10
Lucy Dorrell, University of Oxford, UK
Novel Engineered Immune-Mobilizing T Cell Receptors-Based Drugs (‘ImmTAVs’) to Clear HIV Infection

Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD

Speaker 8 of 10
Bojana Lucic, Universität Heidelberg, Germany
Short Talk: 3D Genome Conformation is the Major Determinant of HIV-1 Integrational Hot-Spots

Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD

Speaker 9 of 10
Alberto Bosque, George Washington University, USA
Short Talk: In vitro, ex vivo and in vivo Analysis of Benzotriazine Derivatives as Latency-Reversing Agents

Thursday, March 28 | 8:00AM - 11:15AM
Targeting and Eradication of HIV
Room: Macdonald CD

Speaker 10 of 10
Marion Pardons, Université de Montréal, CRCHUM, Canada
Short Talk: Latency Reversing Agents Induce Differential Responses in Distinct Memory CD4+ T Cell Subsets

Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 1 of 10
* James Mark Binley, San Diego Biomedical Research Institute, USA


Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 2 of 10
* Ralf Wagner, Universität Regensburg, Germany


Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 3 of 10
Richard T. Wyatt, IAVI Neutralizing Antibody Center, The Scripps Research Institute, USA
NFL Trimers: Down the Rabbit Hole and Other Unlikely Events


Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 4 of 10
David Peterhoff, University Regensburg, Germany
Short Talk: Stabilized HIV-1 Clade C Envelope Trimers with Increased Stability and Preferential Antigenic Properties in vitro and in vivo


Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 5 of 10
Tongqing Zhou, NIAID, National Institutes of Health, USA
Native Glycan Shield Is Important for Inducing Immune Responses that Neutralize Diverse Tier-2 Viruses in Sequential HIV-1 Env Trimer Immunization


Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB


Coffee Break


Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 7 of 10
Andrew J. Borst, University of Washington, USA
Short Talk: Germline VRC01 Antibody Recognition of a Modified Clade C HIV-1 Envelope Trimer and a Glycosylated HIV-1 gp120 Core


Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 8 of 10
Karin Loré, Karolinska Institutet, Sweden
In vivo Fate of Env and Early Responses upon Immunization


Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 9 of 10
Derek T. O'Hagan, GlaxoSmithKline Vaccines, USA
Designing and Building the Next Generation of Vaccine Adjuvants


Thursday, March 28 | 8:00AM - 11:15AM
Env Immunogen Design and Evaluation
This session is from HIV Vaccines
Room: Macdonald AB

Speaker 10 of 10
Aleksandar Antanasijevic, The Scripps Research Institute, USA
Short Talk: Development of Self-Assembling Nanoparticle Systems for Presentation of HIV Env Trimers


Thursday, March 28 | 11:15AM - 5:00PM
On Own for Lunch


Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 1 of 10
* Susana T. Valente, Scripps Florida, USA

Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 2 of 10
* Tristan Alexander Scott, City of Hope, USA

Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 3 of 10
Ya-Chi Ho, Yale School of Medicine, USA
Filgotinib, a Janus Kinase Inhibitor, Suppresses HIV-1 Expression and T Cell Activation

Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 4 of 10
Haitao Hu, University of Texas Medical Branch, USA
A Novel Small Molecule Modulating BRD4 to Epigenetically Suppress HIV

Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 5 of 10
Seohyun Ahn, ST Pharm. Co., Ltd., South Korea
A Highly Potent and Safe Allosteric HIV-1 Integrase Inhibitor: Virological, Molecular and Preclinical Characterization of STP0404

Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 6 of 10
Konstantinos Georgiou, University of California, San Francisco, USA
Single-Cell Sequencing Reveals Transcriptome and Surfaceome Signatures of HIV Latently-Infected Cells

Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 7 of 10
Vera Klemm, Kirby Institute, Australia
Nanoparticle Delivery of Epigenetic Silencing siRNA to the Nucleus of HIV-1-Infected Cells

Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 8 of 10
George B. Kyei, University of Ghana, Ghana
Splicing Factor 3B Subunit 1 Interacts HIV Tat and Can Be Targeted to Prevent Viral Transcription and Reactivation from Latency

Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 9 of 10
Ulf Dittmer, University of Duisburg-Essen, Germany
HIV Cure Strategies with Interferon Alpha Subtype 14 in HIV-1 Infected Humanized Mice

Thursday, March 28 | 2:30PM - 4:30PM
Workshop 2: LRA and New Antiviral Strategies
Room: Macdonald CD

Speaker 10 of 10
Miriam Rosas-Umbert, AIDS Research Institute Irsicaixa – HIVACAT, Spain
In vivo Effects of Romidepsin in the Bcn02 Kick&Kill Trial for HIV Remission

Thursday, March 28 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Thursday, March 28 | 5:00PM - 6:45PM
Protect and Kill Strategies to a Functional Cure
Room: Macdonald CD

Speaker 1 of 6
* Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA

Thursday, March 28 | 5:00PM - 6:45PM
Protect and Kill Strategies to a Functional Cure
Room: Macdonald CD

Speaker 2 of 6
* Betty Poon, NIAID, National Institutes of Health, USA

Thursday, March 28 | 5:00PM - 6:45PM
Protect and Kill Strategies to a Functional Cure
Room: Macdonald CD

Speaker 3 of 6
Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Genome Engineering Strategies to Generate HIV-Resistant Cells

Thursday, March 28 | 5:00PM - 6:45PM
Protect and Kill Strategies to a Functional Cure
Room: Macdonald CD

Speaker 4 of 6
Scott G. Kitchen, University of California, Los Angeles AIDS Institute, USA
Engineering Long-Term HIV-Specific Immunity through Chimeric Antigen Receptors and Stem Cells

Thursday, March 28 | 5:00PM - 6:45PM
Protect and Kill Strategies to a Functional Cure
Room: Macdonald CD

Speaker 5 of 6
Kevin V. Morris, Center for Gene Therapy, City of Hope, USA
Flare, Excise, Kill: Means to a Functional Cure for HIV

Thursday, March 28 | 5:00PM - 6:45PM
Protect and Kill Strategies to a Functional Cure
Room: Macdonald CD

Speaker 6 of 6
Chris Peterson, Fred Hutchinson Cancer Research Center, USA
Short Talk: Trafficking of Stem Cell-Derived CAR T-Cells to B-Cell Follicles in SHIV-Infected Nonhuman Primates

Thursday, March 28 | 5:00PM - 6:45PM
From the Lab to the Clinic: A Reality Check for Investigator
s
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 1 of 6
* Devin Sok, International AIDS Vaccine Initiative, USA


Thursday, March 28 | 5:00PM - 6:45PM
From the Lab to the Clinic: A Reality Check for Investigator
s
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 2 of 6
* Silvija I. Staprans, Bill & Melinda Gates Foundation, USA


Thursday, March 28 | 5:00PM - 6:45PM
From the Lab to the Clinic: A Reality Check for Investigator
s
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 3 of 6
Mark Connors, NIAID, National Institutes of Health, USA
Impact of Immunogen Design and Replication on Pre-Clinical and Clinical Immunogenicity


Thursday, March 28 | 5:00PM - 6:45PM
From the Lab to the Clinic: A Reality Check for Investigator
s
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 4 of 6
Peter D. Kwong, NIAID, National Institutes of Health, USA
Short Talk: Steps Toward a Fusion Peptide-Based Vaccine


Thursday, March 28 | 5:00PM - 6:45PM
From the Lab to the Clinic: A Reality Check for Investigator
s
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 5 of 6
Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V., Netherlands
Advancing an HIV Vaccine Candidate through the Development Pipeline: A View from Industry


Thursday, March 28 | 5:00PM - 6:45PM
From the Lab to the Clinic: A Reality Check for Investigator
s
This session is from HIV Vaccines

Room: Macdonald AB

Speaker 6 of 6
Antu K. Dey, International AIDS Vaccine Initiative, USA
Translation of Multiple Products from Discovery to the Clinic: The View from a Product Development Center at a Non-Profit Organization


Thursday, March 28 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Macdonald CD


Thursday, March 28 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
This session is from HIV Vaccines
Room: Macdonald AB


Thursday, March 28 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac/Empress
No registration fees are used to fund alcohol served at this function.

Thursday, March 28 | 8:00PM - 11:00PM
Entertainment
Room: Frontenac/Empress
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, March 28 | 8:00PM - 11:00PM
Cash Bar
Room: Frontenac/Empress


Friday, March 29 | 10:24AM - 10:24AM
Departure


*Session Chair
†Invited, not yet responded.